Clinical Read2026-08-13
ST-01156
BeyondSpring Inc.BYSI
- Indication
- Solid tumors
- Stage
- phase0
- Event
- IND-Enabling
- Details
August 13, 2026: SEED Therapeutics Inc. received FDA orphan drug designation for a small molecule degrader of RNA-binding motif protein 39 for the treatment of neuroblastoma. The designation status is listed as designated, and the product is not FDA approved for the orphan indication.
- Source
- View catalyst source ↗